<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769169</url>
  </required_header>
  <id_info>
    <org_study_id>DREAM STUDY</org_study_id>
    <nct_id>NCT02769169</nct_id>
  </id_info>
  <brief_title>Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy</brief_title>
  <official_title>Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy: A Prospective Randomized Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether double-dose Ranibizumab are effective to
      regress the polyps and benefit to the visual outcome in the polypoidal choroidal vasculopathy
      (PCV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, it's reported that intravitreal high dose Lucentis®（Ranibizumab） could benefit to
      both regression of the polyps and the relief of macular edema in PCV patients. Since it was a
      single arm prospective study with a relatively small sample size, randomized clinical trials
      were needed to confirm the efficacy of high dose Ranibizumab in PCV treatment. In this study,
      the investigator will compare the efficacy of double-dose (1mg, 3+prn) Raibizumab with
      regular dose (0.5mg, 3+prn) for PCV treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who have at least 1 polyp resolution</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants who have at least 1 polyp resolution, assessed by Indocyanine angiography (ICGA) between baseline and Month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of best corrected visual acuity(BCVA)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Mean change in BCVA, from baseline to the end of 6 month. As assessed by changes of number of letters with the ETDRS (Early Treatment of Diabetic Retinopathy Study) chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of central foveal thickness</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Mean change of central foveal thickness, from baseline to the end of 6 month. As assessed by optical coherence tomography scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection frequency</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Average injection number(from baseline to the end of 6 month), assessed by the number of intravitreal injection from baseline to month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis: number of adverse event</measure>
    <time_frame>6 months</time_frame>
    <description>Serious ocular adverse events in the study eye, including reduced VA, retinal hemorrhage, endophthalmitis, corneal edema, iridocyclitis, macular degeneration, retinal artery occlusion, retinal tear, retinal vein occlusion and vitreous floaters. Antiplatelet Trialists' Collaboration (APTC) arterial thromboembolic events (ATEs): including deaths (vascular or unknown cause), nonfatal myocardial infarction and hemorrhagic or ischemic nonfatal cerebrovascular accident. Serious adverse event of special interest, including ATE, bleeding/hemorrhage in central nervous system (CNS) or non-CNS, congestive heart failure, fistulae, gastrointestinal perforation, hypertension, venous thrombotic events and wound healing complications.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>double-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-dose
Lucentis® (Raibizumab), 1mg, 3+prn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>regular-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>regular-dose
Lucentis® (Raibizumab), 0.5mg, 3+prn</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis® (Raibizumab) double-dose</intervention_name>
    <description>Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.</description>
    <arm_group_label>double-dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis® (Raibizumab) regular-dose</intervention_name>
    <description>Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn</description>
    <arm_group_label>regular-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 50 years and ≤80;

          -  Active PCV confirmed by ICGA+FFA (Indocyanine green angiography + fundus fluorescein
             angiography);

          -  At least one distinguishable polyp was shown in ICGA;

          -  BCVA between 24 to 73 letters with ETDRS chart (Early Treatment of Diabetic
             Retinopathty Study);

          -  The greatest linear dimension of the lesion &lt;5400μm.

        Exclusion Criteria:

          -  Previously received treatment of laser retina photocoagulation, transpupillary
             thermotherapy, pneumatic displacement of subretinal blood or any investigational
             treatment;

          -  Previous photodynamic therapy or anti-Vegf treatment within 6 months in study eye

          -  Previously received treatment of photodynamic treatment within 1 month, or any
             anti-vascular endothelial growth factor (VEGF) intraocular injection in 3 months in
             the fellow eye;

          -  Combine of current vitreous hemorrhage or extensive subretinal hemorrhage (lesion area
             &gt;30mm2);

          -  A history of angioid streaks, presumed ocular histoplasmosis syndrome or pathologic
             myopia;

          -  Experienced retinal pigmental epithelium (RPE) tear, retinal detachment, macular hole
             or uncontrolled glaucoma;

          -  Undergone intraocular surgery (except uncomplicated cataract extraction with
             intraocular lens implantation);

          -  Cataract extraction with intraocular lens implantation within 60 days;

          -  Combine of cataract that could require medical or surgical intervention during 12
             months;

          -  Combine of diabetes mellitus and have poor glucose control (Haemoglobin A1c (HbA1c)
             &gt;8%);

          -  Combine of hypertension and have poor blood pressure control (blood pressure ≥140/95
             mmHg after regular antihypertensive drugs treatment);

          -  History of myocardial infarction or cerebral infarction in last 6 months;

          -  During gestation period or lactation period;

          -  Combine of confirmed systemic autoimmune disease or any uncontrollable clinical
             conditions (e.g. HIV, malignant tumor, active hepatitis, severe systemic disease,
             diseases need immediately surgical treatment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Lu, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center Guangzhou, Guangdong China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoyan Ding, MD, phD</last_name>
    <phone>+86-135-3502-2222</phone>
    <email>dingxy75@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Lu, MD, phD</last_name>
    <phone>+86-18922103816</phone>
    <email>lulin888@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Ding, Ph.D</last_name>
      <phone>+86-135-3502-2222</phone>
      <email>dingxy75@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lin Lu, Ph. D</last_name>
      <phone>+86-189-2210-3816</phone>
      <email>lulin888@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Retina surgery department, Shenzhen Eye Hospital of Second Clinical Medical College of Jinan University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoming Zhang, Ph.D</last_name>
      <email>zhang-guoming@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ruyin Tian, Master</last_name>
      <phone>+86-158-1181-0253</phone>
      <email>308586564@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Xuzhou</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suyan Li, Ph.D</last_name>
      <phone>+86-138-5210-1775</phone>
      <email>lisuyan1226@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Haiyang Liu, Master</last_name>
      <phone>+86-136-8516-7216</phone>
      <email>liuhaiyang86@126.com,</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dept. of Ophthalmology，Minhang hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Peng, Ph.D</last_name>
      <email>drqingpeng@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Tianyu Wang, Master</last_name>
      <phone>+86-138-1753-2267</phone>
      <email>13817532267@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013 May;120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014. Epub 2013 Jan 23.</citation>
    <PMID>23352196</PMID>
  </results_reference>
  <results_reference>
    <citation>Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012 Sep;32(8):1453-64.</citation>
    <PMID>22426346</PMID>
  </results_reference>
  <results_reference>
    <citation>Kokame GT. Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2014 Jul;112:74-93.</citation>
    <PMID>25646029</PMID>
  </results_reference>
  <results_reference>
    <citation>Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol. 2010 Mar;94(3):297-301. doi: 10.1136/bjo.2008.150029. Epub 2009 Sep 1.</citation>
    <PMID>19726427</PMID>
  </results_reference>
  <results_reference>
    <citation>Obata R, Yanagi Y, Kami J, Takahashi H, Inoue Y, Tamaki Y. Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration. Jpn J Ophthalmol. 2006 Jul-Aug;50(4):354-360. doi: 10.1007/s10384-005-0337-2.</citation>
    <PMID>16897221</PMID>
  </results_reference>
  <results_reference>
    <citation>Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, Nishikawa M, Mitsuma Y, Yamazaki Y, Matsumura M, Uyama M. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003 Oct;121(10):1392-6.</citation>
    <PMID>14557174</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>July 10, 2016</last_update_submitted>
  <last_update_submitted_qc>July 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lin Lu</investigator_full_name>
    <investigator_title>MD, PhD，Zhongshan Ophthalmic Center</investigator_title>
  </responsible_party>
  <keyword>Ranibizumab, regression of the polyps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

